Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the efficacy, safety and tolerability of alisporivir for the treatment of hospitalised patients with infections due to SARS-CoV-2 (COVID-19). A randomised, open-label, proof of concept, Phase 2 study

X
Trial Profile

Evaluation of the efficacy, safety and tolerability of alisporivir for the treatment of hospitalised patients with infections due to SARS-CoV-2 (COVID-19). A randomised, open-label, proof of concept, Phase 2 study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alisporivir (Primary) ; Alisporivir (Primary)
  • Indications SARS-CoV-2 acute respiratory disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CYCLOVID
  • Most Recent Events

    • 09 May 2023 Status changed from recruiting to completed.
    • 18 Jan 2021 According to a Debiopharm media release, the first patient has been dosed in this study.
    • 18 Jan 2021 Status changed from not yet recruiting to recruiting, according to a Debiopharm media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top